Clinical trials: Metabolism and Elimination
Safety and Pharmacokinetics in Healthy Volunteer Subjects
A Phase 1 Open-Label Study to Evaluate the Metabolism and Excretion of CC-223 and the Effect of Food on the Pharmacokinetics of CC-223 in Healthy Male Adult Subjects
Part 1: To characterize the biotransformation and excretion of CC-223 following a single 20-mg oral dose of CC-223 capsule containing a microtracer of [14C]-CC-223 solution in healthy male subjects; and to evaluate the…
- Trial name
- AME/FE (NCT01611467)
- Testing
- CC-223
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Celgene
Type 2 Diabetes Mellitus
Correlation Between Change of HbA1c, Urinary Glucose Excretion and Other Factors in Patients Treated With Ipragliflozin
The purpose of this study is to examine the correlation between change of HbA1c, urinary glucose excretion and other factors when ipragliflozin is added to preexisting therapy in subjects with type 2 diabetes.
- Trial name
- NCT02791035
- Testing
- Oral administration of Ipragliflozin
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Asan Medical Center
Respiratory Syncytial Virus Infections
A Phase 1, Open-Label Study of the Absorption, Metabolism, Excretion and Absolute Bioavailability of ALS-008176
The purpose of this study is to see how ALS-008176 is taken up, broken down, and removed from the body.
- Trial name
- NCT02231671
- Testing
- ALS-008176, ALS-008112
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Healthy Volunteers
A Mass Balance Study Following Subcutaneous Administration of [14C]-ITI-1284 to Healthy Male Subjects
ITI-1284-012 is an open-label, single-dose study to assess the mass balance recovery of radioactivity, and to evaluate the pharmacokinetics, safety and tolerability of ITI-1284 after a single subcutaneous dose of [14C]-ITI-1284…
- Trial name
- NCT06786286
- Testing
- [14C]-ITI-1284
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Intra-Cellular Therapies, Inc.
Healthy Volunteers
A Study to Evaluate the Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability of AG-348 in Healthy Male Participants Following Administration of a Single Oral Dose of [14C]AG-348 and Concomitant Single Intravenous Microdose of [13C6]AG-348
This study will assess absorption, distribution, metabolism, excretion and absolute bioavailability of AG-348 in healthy male participants.
- Trial name
- NCT03703505
- Testing
- AG-348, [13C6]AG-348
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Agios Pharmaceuticals, Inc.
Healthy Adult Male Volunteers
ADME Study of [14C]- Larotinib in Healthy Male Subjects
Study to Evaluate the Mass Balance and Biotransformation of Single Dose [14C]-Larotinib（Z650）in healthy male subjects.
- Trial name
- NCT05059743
- Testing
- [14C]-Larotinib
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Healthy
A Study of [14C]-LY3866288 in Healthy Participants
The main purpose of this study is to evaluate how much of the study drug (LY3866288), administered as a single dose that has the radioactive substance 14C incorporated into it, passes from blood into urine, feces and expired air…
- Trial name
- NCT06644378
- Testing
- [14C]-LY3866288, LY3866288
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Cardiovascular Disease
Absolute Bioavailability and ADME Study of [14C]AZD9977 in Healthy Male Subjects
Study to Assess the Absorption, Metabolism, and Excretion of [14C]AZD9977 after a Single-Dose Oral Administration
- Trial name
- NCT04686591
- Testing
- AZD9977 capsule 50 mg, [14C]AZD9977 Solution for Infusion, 20 µg/mL (NMT 37.0 kBq/5 mL), [14C]AZD9977 Oral Suspension, 100 mg (NMT 9.9 MBq)
- Where
- United Kingdom
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Helicobacter Pylori Infection
Human Mass Balance and Biotransformation Study of [14C]TNP-2198
The purpose of the study is to analyze absorption, metabolism, excretion, mass balance and biotransformation after a single oral dose of [14C]TNP-2198 in healthy male participants
- Trial name
- NCT06137573
- Testing
- [14C]TNP-2198
- Where
- China
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- TenNor Therapeutics (Suzhou) Limited
Healthy Volunteers
TAK-385 Phase I Absorption, Distribution, Metabolism, Excretion and Absolute Bioavailability Study
The purpose of this 2 part study is to look at how TAK-385 is taken up, broken down and removed from the body when given as a radiolabelled oral solution (by mouth) or as an oral tablet (by mouth) followed by a radiolabelled…
- Trial name
- NCT02252354
- Testing
- [14C]-TAK-385 Oral Solution, TAK-385 Tablets, [14C]-TAK-385 Solution for Intravenous Infusion
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Takeda
Metabolism and Elimination
An Open-label, Single Dose Study to Determine the Metabolism and Elimination of [14C]E2609 in Healthy Male Subjects
This is an open-label, single dose study in healthy male subjects.
- Trial name
- NCT01975636
- Testing
- E2609
- Where
- 2 sites in United States
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Healthy Volunteers
How [14C]-JNT-517 is Absorbed, Broken Down, and Removed From the Body After a Single Oral Dose in Healthy Male Participants
The purpose of this study is to determine the absorption, metabolism and excretion of [14C]-JNT-517 and to characterize and determine the metabolites present in plasma, urine, and feces in healthy male participants following a…
- Trial name
- NCT07573449
- Testing
- [14C]-JNT-517
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Pain
Investigation of Rate + Extent of Excretion of Radioactivity in Urine +Faeces After Oral Administration of [14C]AZD2066
The aim of this study is to get information about absorption, distribution, metabolism and excretion as well as the tolerability and safety of AZD2066 in healthy male volunteers.
- Trial name
- NCT00829088
- Testing
- AZD2066
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Neuropathic Pain
Absorption, Metabolism, and Excretion Study of BIIB074
The primary objectives of the study are: To determine the mass balance and routes of elimination of BIIB074 and its known metabolites following administration of a single oral dose of BIIB074 in healthy male participants and To…
- Trial name
- NCT02751905
- Testing
- BIIB074
- Where
- United States
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Biogen
Suspected Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Up to 40 evaluable women with known or suspected epithelial ovarian, fallopian tube, or primary peritoneal cancer will participate in two different imaging cohorts.
- Trial name
- NCT02637934
- Testing
- [18F]FluorThanatrace, PET/CT imaging sessions
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Cancer
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
GSK1120212 is a reversible and highly selective allosteric inhibitor of MEK1 and MEK2 activation and kinase activity currently being developed for the treatment of malignant melanoma.
- Trial name
- NCT01387204
- Testing
- GSK1120212
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- GlaxoSmithKline
Acinetobacter Baumannii-calcoaceticus Complex Infections
Study to Determine the Excretion and Metabolism of 14C-ETX2514 Administered Intravenously in Healthy Male Subjects
This study will be conducted to determine the routes and rates of excretion of radio label arising from 14C-ETX2514 and to characterize metabolites of ETX2514 arising from 14C-ETX2514 administered intravenously in healthy…
- Trial name
- NCT04018950
- Testing
- ETX2514, 14C-ETX2514
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Entasis Therapeutics
Intestinal Disorders, Bowel Diseases, Inflammatory
TD-1473 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects
This is an open-label, 2-cohort study to evaluate the absolute bioavailability, absorption, distribution, metabolism and excretion of TD-1473 in healthy male subjects.
- Trial name
- NCT03408470
- Testing
- TD-1473 oral capsule, [14C]-TD-1473 IV bolus, [14C]-TD-1473 Oral Capsule
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Theravance Biopharma
Insulin Resistance
The Influence of Rosiglitazone on the Diuretic Effect of Furosemide and Amiloride
Thiazolidinedione derivates (TZD's) are Peroxisome-Proliferator-Activated-Receptor-γ agonists (PPARγ-agonists) and enhance insulin sensitivity.
- Trial name
- NCT00285805
- Testing
- response (sodium excretion) to amiloride infusion, response (sodium excretion) to furosemide infusion
- Where
- Netherlands
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Healthy
Single Dose Absorption, Distribution, Metabolism, and Excretion Study of [14C]-CORT113176 in Healthy Male Participants
This study will evaluate the mass balance recovery and metabolite profile, and will identify metabolite structures following a single oral dose of [14C]-CORT113176 in healthy male participants.
- Trial name
- NCT04990310
- Testing
- [14C]-CORT113176
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics